Vestibular schwannoma (acoustic neuroma)
Prepared with OnCo (onco.cc/prep/vestibular-schwannoma/). Orientation, not medical advice; your team knows your case.
My details
What I know, what is unclear, changes to discuss
Saved in this browserMy questions
14 on the sheet- 1.What is my exact diagnosis, stage, and grade, and which tests established them?
- 2.Which biomarkers have been tested on my tumour (for example Tumour size and growth on serial MRI, Pure-tone audiometry and word recognition, Germline NF2 testing when bilateral, young or with other schwannomas or meningiomas, Facial nerve functionbefore and after treatment), and what were the results?
- 3.Which subtype is my cancer, and does that change the recommended treatment?
- 4.Is germline (inherited) genetic testing recommended for me or my family?
- 5.For my situation (small tumour, stable or good hearing), which of the standard options do you recommend and why?
- 6.For my situation (growing small or medium tumour), which of the standard options do you recommend and why?
- 7.For my situation (large tumour with brainstem compression or hydrocephalus), which of the standard options do you recommend and why?
- 8.For my situation (nf2-related schwannomatosis, progressive tumour or falling hearing), which of the standard options do you recommend and why?
- 9.Am I a candidate for Bevacizumab, Brigatinib, and what side effects should I expect?
- 10.Are there clinical trials I could join, for example of Brigatinib, Bevacizumab, Stereotactic radiosurgery (Gamma Knife, CyberKnife, linac SRS)?
- 11.Would a second opinion at a high-volume centre change anything, and can you help arrange it?
- 12.What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?
- 13.I read that “No approved drug for NF2-related schwannomatosis; bevacizumab is off label and its effect wanes”. How does that affect my plan?
- 14.I read that “Predicting which small tumours will grow, so that the rest can be left alone”. How does that affect my plan?
The words I may hear
- Stereotactic radiosurgery (SRS): A single high dose of radiation delivered to a brain tumour or metastasis by beams converging from all sides, so the target gets a destructive dose while the surrounding brain gets little; no scalpel is involved despite the name.
Tests and results to bring
Biomarker results to ask for: Tumour size and growth on serial MRI (Koos grade), Pure-tone audiometry and word recognition (hearing class), Germline NF2 testing when bilateral, young or with other schwannomas or meningiomas, Facial nerve function (House-Brackmann grade) before and after treatment.
Scans and tests linked to this cancer: Active surveillance, MRI.
Bring copies of scan reports, pathology and blood results, and a list of every medicine and supplement.
The treatments I may be offered
- Small tumour, stable or good hearing: Observation with MRI and audiometry, typically yearly; treatment on documented growth or hearing decline. (Active surveillance, MRI)
- Growing small or medium tumour: Stereotactic radiosurgery (Gamma Knife, CyberKnife or linac) at about 12 to 13 Gy, or fractionated stereotactic radiotherapy; microsurgery in younger patients or by preference. (Stereotactic radiosurgery (Gamma Knife, CyberKnife, linac SRS), Gamma Knife, CyberKnife robotic radiosurgery, IMRT / IGRT (modern external beam))
- Large tumour with brainstem compression or hydrocephalus: Microsurgical resection with facial nerve monitoring, sometimes deliberately subtotal followed by radiosurgery to the remnant; shunting for hydrocephalus. (Stereotactic radiosurgery (Gamma Knife, CyberKnife, linac SRS), MRI)
- NF2-related schwannomatosis, progressive tumour or falling hearing: Bevacizumab (off label, phase 2 evidence) to shrink tumours and improve hearing; brigatinib on INTUITT-NF2 evidence; hearing rehabilitation with cochlear or auditory brainstem implants; surgery and radiosurgery used selectively. (Bevacizumab, Brigatinib)
From the standard of care recorded for this cancer; which apply depends on your stage and biomarkers. Ask which the team recommends and why.